Search Results
3
Study Matches
Site for HEALEY ALS Platform Trial - Master Protocol
The HEALEY ALS Platform Trial is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. The trial is designed as a perpetual platform trial. This means that there is a single Master Protocol determining the conduct of the trial.
Heidi Runk at hrunk@pennstatehealth.psu.edu or 717-531-0003, ext=287177
All
18 year(s) or older
NCT04297683
Neurology
Site for Therapy in Amyotrophic Lateral Sclerosis (TAME)
This is a phase IIB multi-centered, double blind, placebo controlled study to assess the safety and efficacy of a medication called memantine in people with ALS. This study is designed to validate the preliminary data that suggests memantine can slow down the course of ALS and also to determine if memantine can improve ALS patients who have characteristics of frontotemporal dementia.
Anne Haulman at ahaulman@pennstatehealth.psu.edu or 717-531-0003, ext=289123
All
18 year(s) or older
NCT02118727
Neurology
A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
Anne Haulman at ahaulman@pennstatehealth.psu.edu or 717-531-0003, ext=289123
All
18 year(s) or older
NCT04165824
Neurology